<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Annual Conference on FinanClub</title>
    <link>https://finan.club/tags/annual-conference/</link>
    <description>Recent content in Annual Conference on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 06 Jan 2024 09:07:28 +0000</lastBuildDate><atom:link href="https://finan.club/tags/annual-conference/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PFE</title>
      <link>https://finan.club/us/pfe/</link>
      <pubDate>Sat, 06 Jan 2024 09:07:28 +0000</pubDate>
      
      <guid>https://finan.club/us/pfe/</guid>
      <description>score:-20
Chances: Pfizer&amp;rsquo;s gene therapy approval in Canada for hemophilia B indicates a potential for growth in the rare disease treatment market.Pfizer&amp;rsquo;s acquisition of Seagen Inc. and the expected financial impact for FY24 demonstrate the company&amp;rsquo;s strategic expansion and growth plans.Pfizer&amp;rsquo;s participation in the 42nd Annual J.</description>
    </item>
    
  </channel>
</rss>
